| Assessment Status | Rapid Review Complete |
| HTA ID | 24042 |
| Drug | Empagliflozin |
| Brand | Jardiance® |
| Indication | Empagliflozin is indicated in adults for the treatment of chronic kidney disease. |
| Assessment Process | |
| Rapid review commissioned | 09/10/2024 |
| Rapid review completed | 22/11/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that empagliflozin be considered for reimbursement for this indication*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
